Savara (NASDAQ:SVRA) Announces Quarterly Earnings Results

Savara (NASDAQ:SVRA) issued its quarterly earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01), FiscalAI reports.

Savara Stock Performance

NASDAQ:SVRA traded down $0.21 during trading hours on Wednesday, reaching $4.12. 1,951,801 shares of the stock were exchanged, compared to its average volume of 1,317,712. The stock has a market capitalization of $712.09 million, a P/E ratio of -8.24 and a beta of 0.45. The firm has a 50 day simple moving average of $3.78 and a 200-day simple moving average of $3.05. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. Savara has a 52 week low of $1.89 and a 52 week high of $4.51.

Analysts Set New Price Targets

SVRA has been the topic of several recent research reports. Citigroup restated an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. Guggenheim raised their price objective on Savara from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Wednesday, October 8th. Oppenheimer increased their target price on Savara from $6.00 to $8.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. Finally, Wells Fargo & Company initiated coverage on Savara in a research report on Monday, October 20th. They set an “overweight” rating and a $7.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.83.

Institutional Investors Weigh In On Savara

Several institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its stake in Savara by 8.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 700,646 shares of the company’s stock valued at $2,501,000 after buying an additional 55,174 shares during the period. BNP Paribas Financial Markets raised its holdings in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in Savara during the second quarter worth approximately $33,000. Nantahala Capital Management LLC lifted its position in Savara by 3.1% in the second quarter. Nantahala Capital Management LLC now owns 8,325,375 shares of the company’s stock worth $18,982,000 after purchasing an additional 250,000 shares during the period. Finally, VR Adviser LLC boosted its stake in Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock valued at $20,256,000 after purchasing an additional 5,626,624 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.